AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02706470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dydrogesterone
Description: Patients will receive oral dydrogesterone 10 mg three times a day for 30 days since the occurrence of positive result in HCG test in urine and 14 consecutive days of elevated basal body temperature.
Study NCT03998033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET140202 autologous T cell product
Description: Autologous T cells transduced with lentivirus encoding an ET140202 expression construct
Study NCT01235247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reminders vs. no reminders
Description: Intervention providers will receive clinical reminders as part of patient care, and control group providers will not receive the reminders
Study NCT02061267 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niacin
Description: The subjects will receive a vitamin B3 supplement (2 g)
Study NCT05337111 — intervention group
Intervention type: OTHER
Intervention: Maximum fat oxidation test
Description: Progressive exercise test to determine maximum fat oxidation during exercise
Study NCT03379259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A333
Description: Anti-PD-L1 antibody
Study NCT03379259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A317
Description: Anti-PD-1 antibodies
Study NCT00473668 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilbrix-Hib
Description: Intramuscular injection, 1 dose
Study NCT00473668 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix™-HepB/ Hiberix™
Description: Intramuscular injection, 1 dose
Study NCT00654836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Participants will receive bevacizumab 15 mg/kg on days 1,22, and 43.
Study NCT00654836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive a standard carboplatin dose according to their area under the plasma drug concentration-time curve (AUC-6) on days 1, 22, and 43.
Study NCT00654836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: Participants will receive ABI-007 (Abraxane) 100mg/m2 on days 1,8, 15, 22, 29, 36,43,and 50.
Study NCT02061267 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saturated meal
Description: Test meal with high-fat (containing 72% saturated fat, 22% carbohydrate, and 6% protein)
Study NCT02061267 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monounsaturated meal
Description: Test meal with high-fat (containing 72% monounsaturated fat, 22% carbohydrate, and 6% protein)
Study NCT01785446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of cisatracurium and sufentanil in different age groups.
Description: For this intervention, we compared the cisatracurium consumption, refractory index and sufentanil consumption between group P1, P2 and P3.
Study NCT02061267 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyunsaturated meal
Description: Test meal with high-fat (containing 72% polyunsaturated omega-3 fat, 22% carbohydrate, and 6% protein)
Study NCT03489720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescribed Exercise Program
Description: Brief cardiovascular exercise training (>70% of maximum heart rate) for 15 minutes a day, 5 days a week for 8 weeks.~The exercise intervention will be a 15-minute per day of vigorous exercise that as monitored by a Fitbit Charge 2.~Examples of possible 15-minute exercise regimens to be used include:~* Walking quickly or running up and down stairs~* Plyometric exercises such as jumping jacks, high knees, squats, lunges, speed skaters, froggers, etc~* Walking up an incline on a treadmill~* Jogging or running on a treadmill or elliptical~* Stationary cycling or rowing
Study NCT03489720 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prescribed Exercise Program
Description: Brief cardiovascular exercise training (>70% of maximum heart rate) for 15 minutes a day, 5 days a week for 8 weeks.~The exercise intervention will be a 15-minute per day of vigorous exercise that as monitored by a Fitbit Charge 2.~Examples of possible 15-minute exercise regimens to be used include:~* Walking quickly or running up and down stairs~* Plyometric exercises such as jumping jacks, high knees, squats, lunges, speed skaters, froggers, etc~* Walking up an incline on a treadmill~* Jogging or running on a treadmill or elliptical~* Stationary cycling or rowing
Study NCT03440996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinpro™ 5000
Description: Clinpro™ 5000 with 1.1% Sodium Fluoride is a new anti-cavity toothpaste, and is currently available and have been shown in some initial case reports to be useful in the reduction of white spot lesions. Clinpro™ restores minerals and helps you produce saliva. The Clinpro™ products are advanced formulas containing an innovative tri-calcium phosphate ingredient. It is available exclusively from 3M ESPE. Clinpro™ contains fluoride as well as calcium and phosphate, which are components naturally found in saliva.
Study NCT03440996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinpro™ Tooth Crème
Description: Clinpro™ Tooth Crème with 0.21% Sodium Fluoride is a new anti-cavity toothpaste, and is currently available and have been shown in some initial case reports to be useful in the reduction of white spot lesions. Clinpro™ restores minerals and helps you produce saliva. The Clinpro™ products are advanced formulas containing an innovative tri-calcium phosphate ingredient. It is available exclusively from 3M ESPE. Clinpro™ contains fluoride as well as calcium and phosphate, which are components naturally found in saliva.
Study NCT03440996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MI-Paste Plus
Description: MI-Paste Plus is a widely used anti-cavity toothpaste on the market and it is used as a control group in this study.
Study NCT02262299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: Receive tablets with pirfenidone
Study NCT02262299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Recieve tablets with placebo
Study NCT04217694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogstate Assessment Battery
Description: Complete CogState testing
Study NCT04217694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Given PO
Study NCT04217694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride
Description: Given PO
Study NCT03489720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Exercise Program
Description: Usual exercise activity for 8 weeks
Study NCT03489720 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Exercise Program
Description: Usual exercise activity for 8 weeks
Study NCT05254067 — intervention group
Intervention type: DEVICE
Intervention: Codman Enterprise 2 Vascular Reconstruction Device
Description: a self-expanding nitinol, compliant, closed-cell, recapturable design that can be deployed by a single operator designed to assist in the stent-assisted coil embolization of intracranial aneurysms, specifically those that have a wide neck that would not otherwise maintain the coil embolization material within the aneurysm because of the wide opening at the base of the aneurysm.
Study NCT01470300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy density feeding study
Description: In a crossover design, adults are served breakfast, lunch, and dinner, 1 day a week for 4 weeks. Meal entrees will vary in energy density (100% and 80%) and the method used to reduce the energy density (added fruit \& vegetables, decreased fat, added plain water).
Study NCT06455488 — intervention group
Intervention type: PROCEDURE
Intervention: Ventricular Tachycardia Ablation
Description: This is a surgical ablation meant to reset patients irregular rhythm back to sinus.
Study NCT06455488 — intervention group
Intervention type: DEVICE
Intervention: ICD Implant
Description: A pacemaker or defibrillator implant to prevent SCD
Study NCT06455488 — intervention group
Intervention type: DRUG
Intervention: Antiarrhythmic drug
Description: Drug therapies
Study NCT06455488 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EKG
Description: Monitoring EKG testing done on registry patients
Study NCT06455488 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardioversion
Description: Monitoring cardioversions on registry patients
Study NCT06455488 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Monitoring echocardiogram testing done on patients
Study NCT00767741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: with heat and massage
Description: For the with intervention group a treatment to the injection site is applied after each insulin bolus injection.
Study NCT00514306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Oral OSI-906 administered on an intermittent schedule at increasing doses until disease progression or unacceptable toxicity
Study NCT03637296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Critical time intervention
Description: Care management offered by individual with experience working with individuals with serious mental illness. The care managers engage individuals before they are discharged from the hospital and work with them in the community to support linkages with medical and behavioral health care providers. Care managers provide problem-solving, advice, and support to maximize patients' engagement in care.
Study NCT03134300 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cytokine from blood
Description: Blood draw- one intraoperative, one 3 weeks postoperative
Study NCT03134300 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Cytokine from blood
Description: Blood draw- one intraoperative, one 3 weeks postoperative
Study NCT00837954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lyostypt® AND Surgicel®
Description: The investigational products are the hemostats Lyostypt® and Surgicel® (=Tabotamp® ). Lyostypt® will be provided in the size 5cm x 8cm, Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage.
Study NCT00837954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lyostypt®
Description: The investigational product is the hemostat Lyostypt®. Lyostypt® will be provided in the size 5cm x 8cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.
Study NCT00837954 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgicel®
Description: The investigational product is the hemostat Surgicel® (=Tabotamp® ). Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage.
Study NCT04114019 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vaginal tactile imager
Description: Vaginal elasticity evaluation using a vaginal tactile imager
Study NCT01078909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)
Description: Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
Study NCT05789147 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tVNS
Description: It is a non-invasive transcutaneous electrical stimulation of the auricular branch of the vagus nerve which innervates the skin of the human ear. These nerve fibers project directly to the solitary tract nucleus (NTS) in the brain stem (6).
Study NCT05789147 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tVNS
Description: Sham stimulation is obtained by placing the stimulation electrode at the level of the earlobe. The stimulation is therefore administered and perceived in an area not innervated by vagal fibers.
Study NCT02573441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jump Math
Description: Jump Math is a workbook based program aimed at improving math skills
Study NCT02573441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed
Description: Cogmed is an online computer program aimed at improving working memory skills
Study NCT02573441 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Liaison Services
Description: Liaison Services will include working closely with schools to help explain the strengths and weaknesses of a child based on cognitive testing and to help with the implementation of recommendations
Study NCT02573441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liaison Services
Description: Liaison Services will include working closely with schools to help explain the strengths and weaknesses of a child based on cognitive testing and to help with the implementation of recommendations
Study NCT02287818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration \<6 mg/dL
Study NCT02287818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Febuxostat
Description: Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration \<6 mg/dL
Study NCT01844466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy and speech therapy
Study NCT05864963 — intervention group
Intervention type: PROCEDURE
Intervention: Medial tab-type fasciocutaneous flap
Description: The flap can be taken in different ways depending on the defect. Once the base of the flap is identified, the posterior edge of the tibia is taken as reference; marking of the tab is performed considering that the posterior incision is located 5 cm from the posterior edge of the tibia, and the anterior incision is located longitudinally of the medial region of the tibial diaphysis, the length of the incision depends on the base of the flap and the defect's size.~The posterior incision is made first in the skin, subcutaneous cellular tissue until the fascia is identified; the subfascial flap is dissected to avoid injuring perforators, dissection is completed up to the anterior edge of the flap, if needed direct cutaneous perforators are ligated; once the subfascial plane has been identified and dissected, the tab is completed in its proximal or distal part according to the previous surgical planning. Later, the tab is rotated to the anterior region of the tibia to cover the defect.
Study NCT02345265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy of tumor
Study NCT02345265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02345265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO
Study NCT01397110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: respiratory and exercise therapy
Description: Conventional therapy with specific respiratory and physical therapy plus mental walking training
Study NCT01121848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Pharmaceutical form:vials of 50 mg/5 mL or 500 mg/50mL Route of administration: IV~Dose regimen:
Study NCT02345265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT02345265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiogram
Study NCT02345265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scan
Study NCT02345265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT02345265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT02345265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01450696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered at a dose of 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
Study NCT01450696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine will be administered at a dose of 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
Study NCT01121848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Pharmaceutical form:vials of 50 mg/5 mL or 500 mg/50mL Route of administration: IV~Dose regimen:
Study NCT03398135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: subcutaneous (SC) injection
Study NCT01516931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks
Study NCT01516931 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: counseling
Description: Placebo monthly by general counseling for 12 months.
Study NCT01138553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200mg capsules daily for 5-28 days
Study NCT03780907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Description: 1 mg of E2007 was administered by mouth once daily.
Study NCT03398135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for risankizumab
Description: subcutaneous (SC) injection
Study NCT03775096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: At the end of Baseline visit, carvedilol 3.125 twice daily will be initiated and maintained for 1 week, increased to 6.25twice daily (dispensed at week 1visit), to 12.5mg twice daily (dispensed at week 2) and a max dose of 25mg twice daily (dispensed at week 4 visit), as tolerated. A subject that cannot tolerate at least a 25 mg daily dose will be excluded from the study. Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose. The project will include a washout period at study end.
Study NCT01450696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered at a dose of 80 mg/m\^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
Study NCT01450696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered at a dose of 80 mg/m\^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
Study NCT01078909 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)
Description: Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
Study NCT02417376 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: piezoelectric ultrasonic scaler (frequency of 28-36 KHz)
Description: Periodontal treatment in the form of scaling and root planing (SRP) is provided to the patients assigned to the experimental group, after baseline examination. Scaling is performed using piezoelectric ultrasonic scaler (frequency of 28-36 KHz) and root planing is performed using area specific Gracey curettes (set of 7 instruments number #1-14). SRP is completed in two appointments of 45 min to 1 hour, within 24 hours period.
Study NCT02417376 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gracey curettes
Description: set of 7 instruments number #1-14
Study NCT01450696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
Study NCT01121848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXALIPLATIN
Description: Pharmaceutical form: Lyophilized powder for injection (50 mg/vial or 100 mg/vial) or aqueous solution (50 mg/10 mL and 100 mg/20 mL) Route of administration: IV~Dose regimen:
Study NCT01121848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: Pharmaceutical form: vials of 5 g/100mL Route of administration: IV~Dose regimen: